These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 35047122)

  • 1. Efficacy of omarigliptin, once-weekly dipeptidyl peptidase-4 inhibitor, in patients with type 2 diabetes.
    Kawasaki E; Nakano Y; Fukuyama T; Uchida A; Sagara Y; Tamai H; Tojikubo M; Hiromatsu Y; Koga N
    World J Diabetes; 2021 Dec; 12(12):2087-2095. PubMed ID: 35047122
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dynamics of switching, adherence, and persistence of dipeptidyl peptidase-4 inhibitors use: A nationwide cohort study.
    Ofori-Asenso R; Ilomaki J; Chin KL; Mazidi M; Zomer E; Bell JS; Magliano DJ; Liew D
    Diabetes Res Clin Pract; 2019 Dec; 158():107909. PubMed ID: 31697992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment Burden on Once-Weekly Omarigliptin Versus Daily Dipeptidyl Peptidase-4 Inhibitors in Patients with Type 2 Diabetes: Randomized Controlled Trial (ONWARD-DPP4 Study).
    Ishii H; Kamei N; Shimono D; Niiya T; Tosaki T; Kitazawa T; Suzuki D; Wakasa Y; Seino H; Oishi M; Ohashi H; Higami K; Akai H;
    Diabetes Ther; 2023 Oct; 14(10):1639-1658. PubMed ID: 37468684
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Randomized Controlled Trial of Vildagliptin Versus Alogliptin: Effective Switch From Sitagliptin in Patients With Type 2 Diabetes.
    Shigematsu E; Yamakawa T; Oba MS; Suzuki J; Nagakura J; Kadonosono K; Terauchi Y
    J Clin Med Res; 2017 Jul; 9(7):567-572. PubMed ID: 28611856
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of omarigliptin on glucose variability and oxidative stress in type 2 diabetes patients: A prospective study.
    Ohara M; Nagaike H; Fujikawa T; Kohata Y; Ogawa M; Omachi T; Sasajima R; Chiba H; Ara T; Sugawara A; Hiromura M; Terasaki M; Mori Y; Fukui T; Hirano T; Yokoyama H; Yamagishi SI
    Diabetes Res Clin Pract; 2021 Sep; 179():108999. PubMed ID: 34390762
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Patient Satisfaction of the Weekly DPP-4 Inhibitors Trelagliptin and Omarigliptin in 80 Japanese Patients with Type 2 Diabetes.
    Tosaki T; Kamiya H; Yamamoto Y; Himeno T; Kato Y; Kondo M; Yamada Y; Inagaki A; Tsubonaka K; Oshiro C; Katayama T; Hayasaki T; Nakaya Y; Fujiyoshi H; Nakamura J
    Intern Med; 2017 Oct; 56(19):2563-2569. PubMed ID: 28883229
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Omarigliptin for the treatment of type 2 diabetes.
    Tan X
    Endocrine; 2016 Oct; 54(1):24-31. PubMed ID: 27372109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of the Once-Weekly DPP4 Inhibitor Omarigliptin on Glycemic Control in Patients with Type 2 Diabetes Mellitus on Maintenance Hemodialysis: A 24-Week Open-Label, Multicenter Randomized Controlled Study.
    Yoshizawa Y; Hosojima M; Kabasawa H; Tanabe N; Ugamura D; Koda Y; Shimada H; Takasawa T; Ito T; Kitamura T; Kobayashi M; Suzuki Y; Narita I; Saito A
    Diabetes Ther; 2021 Mar; 12(3):655-667. PubMed ID: 33474645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Randomized, Placebo-Controlled Trial Evaluating the Safety and Efficacy of Adding Omarigliptin to Antihyperglycemic Therapies in Japanese Patients with Type 2 Diabetes and Inadequate Glycemic Control.
    Gantz I; Okamoto T; Ito Y; Sato A; Okuyama K; O'Neill EA; Engel SS; Lai E;
    Diabetes Ther; 2017 Aug; 8(4):793-810. PubMed ID: 28589493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of vildagliptin, sitagliptin, and linagliptin as add-on therapy in Chinese patients with T2DM inadequately controlled with dual combination of insulin and traditional oral hypoglycemic agent.
    Tang YZ; Wang G; Jiang ZH; Yan TT; Chen YJ; Yang M; Meng LL; Zhu YJ; Li CG; Li Z; Yu P; Ni CL
    Diabetol Metab Syndr; 2015; 7():91. PubMed ID: 26500706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Durability of Effectiveness Between Users of Once-Weekly Semaglutide and Dipeptidyl Peptidase 4 Inhibitors (DPP-4i) in US Adults with Type 2 Diabetes.
    Tan X; Liang Y; Gamble C; King A
    Diabetes Ther; 2024 Feb; 15(2):427-445. PubMed ID: 38060149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efficacy and safety of once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus: A systemic review and meta-analysis.
    Wang X; Li X; Qie S; Zheng Y; Liu Y; Liu G
    Medicine (Baltimore); 2018 Aug; 97(34):e11946. PubMed ID: 30142816
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of Dipeptidyl Peptidase-4 Inhibitors on Hyperglycemia and Blood Cyclosporine Levels in Renal Transplant Patients with Diabetes: A Pilot Study.
    Bae J; Lee MJ; Choe EY; Jung CH; Wang HJ; Kim MS; Kim YS; Park JY; Kang ES
    Endocrinol Metab (Seoul); 2016 Mar; 31(1):161-7. PubMed ID: 26754588
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Patient Satisfaction of Dipeptidyl Peptidase-4 Inhibitor After Switching From Once-Daily DPP-4 Inhibitor to Once-Weekly Regimen.
    Suzuki K; Hasegawa K; Watanabe M
    J Clin Med Res; 2018 Aug; 10(8):641-647. PubMed ID: 29977422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized, double-blind, non-inferiority trial evaluating the efficacy and safety of omarigliptin, a once-weekly DPP-4 inhibitor, or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy.
    Handelsman Y; Lauring B; Gantz I; Iredale C; O'Neill EA; Wei Z; Suryawanshi S; Kaufman KD; Engel SS; Lai E
    Curr Med Res Opin; 2017 Oct; 33(10):1861-1868. PubMed ID: 28548024
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and Efficacy of Omarigliptin (MK-3102), a Novel Once-Weekly DPP-4 Inhibitor for the Treatment of Patients With Type 2 Diabetes.
    Sheu WH; Gantz I; Chen M; Suryawanshi S; Mirza A; Goldstein BJ; Kaufman KD; Engel SS
    Diabetes Care; 2015 Nov; 38(11):2106-14. PubMed ID: 26310692
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic-pharmacodynamic (dipeptidyl peptidase-4 inhibition) model to support dose rationale in diabetes patients, including those with renal impairment, for once-weekly administered omarigliptin.
    Jain L; Chain ASY; Tatosian DA; Hing J; Passarell JA; Kauh EA; Lai E
    Br J Clin Pharmacol; 2019 Dec; 85(12):2759-2771. PubMed ID: 31454094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors.
    Golightly LK; Drayna CC; McDermott MT
    Clin Pharmacokinet; 2012 Aug; 51(8):501-14. PubMed ID: 22686547
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized clinical trial evaluating the efficacy and safety of the once-weekly dipeptidyl peptidase-4 inhibitor omarigliptin in patients with type 2 diabetes inadequately controlled on metformin monotherapy.
    Shankar RR; Inzucchi SE; Scarabello V; Gantz I; Kaufman KD; Lai E; Ceesay P; Suryawanshi S; Engel SS
    Curr Med Res Opin; 2017 Oct; 33(10):1853-1860. PubMed ID: 28547998
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vildagliptin vs liraglutide as a second-line therapy switched from sitagliptin-based regimens in patients with type 2 diabetes: A randomized, parallel-group study.
    Takeshita Y; Takamura T; Kita Y; Otoda T; Kato K; Wakakuri H; Yamada M; Misu H; Matsushima Y; Kaneko S;
    J Diabetes Investig; 2015 Mar; 6(2):192-200. PubMed ID: 25802727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.